Efficacy and Safety of E6011, an Anti ‐Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double‐blind, Placebo‐controlled Phase 2 study

ConclusionThis is the first evidence that E6011, a novel cell trafficking inhibitor targeting the FKN ‐CX3CR1 interaction, is modestly effective at 24 weeks treatment in RA patients, although the primary endpoint was not met.

Source: Arthritis and Rheumatology - October 10, 2020 Category: Rheumatology Authors: Yoshiya Tanaka, Tsutomu Takeuchi, Hisashi Yamanaka, Toshihiro Nanki, Hisanori Umehara, Nobuyuki Yasuda, Fumitoshi Tago, Yasumi Kitahara, Makoto Kawakubo, Kentaro Torii, Seiichiro Hojo, Tetsu Kawano, Toshio Imai Tags: Full Length Source Type: research